Zobrazeno 1 - 10 of 266 pro vyhledávání: '"H Van Hoogstraten"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
P665 Social Media Listening to better Understand the Lived Experience of Individuals With Ulcerative Colitis
Autor: O Auriat, L Lucats, S Badalamenti, A Kruger, M Wiekowski, L Glotfelty, H Van Hoogstraten, C Coulouvrat
Publikováno v: Journal of Crohn's and Colitis. 17:i797-i797
Background Lived experience is a depiction of a person's experiences and decisions, as well as the knowledge gained from these experiences and choices. Despite a wealth of clinical studies and real-world data on ulcerative colitis, large-scale and co
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::362d0fa76df0387bf5bc76854df9792e
https://doi.org/10.1093/ecco-jcc/jjac190.0795
Zobrazit plný text záznamu
4
THU0215 Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab
Autor: E.K. Mangan, A.A. den Broeder, H. van Hoogstraten, Patrick Verschueren, Paul Emery, Q. Dong
Publikováno v: THURSDAY, 14 JUNE 2018.
Background Sarilumab is an IL-6R inhibitor recently approved for the treatment of rheumatoid arthritis (RA). To help clinical decision making, we studied the response rate on open-label sarilumab treatment in patients previously treated with tocilizu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2981b983eaca1734aa7763694dc024d
https://doi.org/10.1136/annrheumdis-2018-eular.1376
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
SAT0212 Sarilumab dose reduction in an open-label extension study in ra patients with inadequate response to tnf inhibitors
Autor: S Jayawardena, Gerd-Rüdiger Burmester, E.K. Mangan, Yong Lin, Roy Fleischmann, H. van Hoogstraten, Paweł Hrycaj
Publikováno v: Poster Presentations.
Background Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 TARGET study (NCT01709578), sarilumab (150 or 200 mg SC q2w) + csDMARDs demonstrated efficacy in adults with active, moderate-to-severe RA and inadequate response or intolerance
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7055b15de99ac48a1ae6b226ef8d20ec
https://doi.org/10.1136/annrheumdis-2017-eular.5155
Zobrazit plný text záznamu
8
FRI0242 Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis
Autor: S Jayawardena, Twj Huizinga, H. van Hoogstraten, W Kampman, Mark C. Genovese
Publikováno v: Poster Presentations.
Background In MOBILITY (NCT01061736), SC sarilumab (150 or 200 mg q2w) + MTX demonstrated efficacy in adults with RA and inadequate response to MTX. The most common TEAEs were infections, neutropenia, injection site reactions, and increased transamin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54213e511b65f2c8e6a99de01bd57b60
https://doi.org/10.1136/annrheumdis-2017-eular.3513
Zobrazit plný text záznamu
9
SAT0202 Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis in the phase 3 monarch study, including subpopulations
Autor: JI Vargas, Gerd-Rüdiger Burmester, Yong Lin, H. van Hoogstraten, Toshio Kimura, E.K. Mangan, Eunwon Lee
Publikováno v: Poster Presentations.
Background Efficacy and safety of sarilumab + csDMARDs in RA patients have been demonstrated. Objectives To compare sarilumab monotherapy with adalimumab monotherapy in the ITT population of adults with active RA from MONARCH (NCT02332590) and across
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::899e80870362c29a7b3730f28fe2d453
https://doi.org/10.1136/annrheumdis-2017-eular.4540
Zobrazit plný text záznamu
10
FRI0240 Rheumatoid arthritis (RA) impact following treatment with sarilumab: patient reported outcomes using the raid scale from two randomized phase III trials
Autor: H. van Hoogstraten, Vibeke Strand, C Proudfoot, Laure Gossec, Toshio Kimura, Sophie Guillonneau, M. Reaney, Chieh I. Chen, E.K. Mangan
Publikováno v: Poster Presentations.
Background Patients with RA experience a variety of signs and symptoms and report significant physical and psychological impairment. The RA Impact of Disease (RAID) scale is a disease-specific measure of the impact of RA on patients9 lives. RAID was
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f700d9b35c9507aeef1fce0c8a9a9aa8
https://doi.org/10.1136/annrheumdis-2017-eular.3448
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje